A French real-world study found that the adalimumab biosimilar SB5 was effective in treating rheumatic or gastrointestinal ...
The approval marks the sixth biosimilar to reference Stelara (ustekinumab), and it will be used to treat several immunology ...
Researchers observe significant shifts in payer preferences for originator vs biosimilar products from 2017 to 2022, ...
Number 3: The phase 3 trial (NCT04966338) found that a biosimilar ocrelizumab candidate (Xacrel) was equivalent to Ocrevus in reducing the annualized relapse rate and showed comparable safety and ...
Veterans with inflammatory bowel disease (IBD) prioritize shared decision-making, transparency, and individualized care in ...
Steve Pickette, PharmD, BCPS, chief clinical pharmacist at InpharmD, highlighted the transformative role of artificial intelligence (AI) in managing biosimilars and generics. He explains that AI can ...